[CAS NO. 327036-89-5] TDZD-8

Name: TDZD-8
Brand: Arctom Scientific
SKU: SLK-S2926

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [327036-89-5]

Store

Catalog

SLK-S2926

Brand

Selleck

CAS

327036-89-5

DESCRIPTION [327036-89-5]

Overview

MDL	MFCD04973552
Molecular Weight	222.26
Molecular Formula	C10H10N2O2S
SMILES	CN1SC(=O)N(CC2=CC=CC=C2)C1=O

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	4.4992 mL	22.4962 mL	44.9924 mL
5 mM	0.8998 mL	4.4992 mL	8.9985 mL
10 mM	0.4499 mL	2.2496 mL	4.4992 mL
50 mM	0.0900 mL	0.4499 mL	0.8998 mL

Description

TDZD-8 (NP 01139) is a non-ATP competitive inhibitor with of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.

Targets

GSK-3β ^[1]

2 μM

In vitro

TDZD-8 acts as a noncompetitive inhibitor of ATP or GS-1 binding. TDZD-8 shows no inhibition of PKA, PKC, Cdk-1/cyclin B or CK-II in kinase assays. TDZD-8 specifically induces cell death of primary leukemia specimens. TDZD-8 ablates leukemia progenitor and stem cells. TDZD-8 treatment induces oxidative stress. TDZD-8 induces cell death with extremely rapid cell death kinetics showing loss of membrane integrity. TDZD-8 inhibits PKC and FLT3 in primary AML specimens.

References

[1] Martinez A, et al. J Med Chem, 2002, 45(6), 1292-1299.
[2] Guzman ML, et al. Blood, 2007, 110(13), 4436-4444.